Note: Ingredients listed on restricted chemical lists
General Information
Revision date
2016-10-01
Product name
Zeniquin Tablets
1.2.1 Relevant identified uses
Antibacterial preparation used in veterinary applications
Icons in SDS
Company Information
company name
Australia Pty Ltd
e-mail address of the competent person responsible for the Safety Data Sheet
australia.animalhealth@zoetis.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H361, H372
Hazard statements
Code
Statements
H361
Suspected of damaging fertility or the unborn child
Section 2
SECTION 2: Hazards identification
Appearance: Beige-colored modified oval shaped tablets
2.1 Classification of the substance or mixture
Reproductive Toxicity: Category 2 Specific target organ systemic toxicity (repeated exposure): Category 1
Signal word
Danger
Hazard statements
H361 - Suspected of damaging fertility or the unborn child H372 - Causes damage to organs through prolonged or repeated exposure
Precautionary statements
P201 - Obtain special instructions before use P202 - Do not handle until all safety precautions have been read and understood P280 - Wear protective gloves/protective clothing/eye protection/face protection P260 - Do not breathe dust/fume/gas/mist/vapors/spray P264 - Wash hands thoroughly after handling P270 - Do not eat, drink or smoke when using this product P308 + P313 - IF exposed or concerned: Get medical attention/advice P405 - Store locked up P501 - Dispose of contents/container in accordance with all local and national regulations
2.3 Other hazards
Short Term: May cause eye irritation (based on components) . There is a risk of photosensitization within a few hours after excessive exposure to quinolones. If excess exposure occurs, avoid direct sunlight and wash skin with soap and water. Long Term: This compound may cause cartilage deterioration in knee joints and adverse reproductive effects (based on animal data). Known Clinical Effects: Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Serious allergic reactions, including anaphylaxis, have been reported. Convulsions, increased intracranial pressure, and toxic psychosis have been reported in patients receiving quinolones. Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
